Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 282-286

  Zhang, Erwei ^a   Zhu, Xuhui ^a   Han, Song ^b   Peng, Zhifeng ^b   Wang, Wei ^a   Li, Junfa ^b   Yang, Yong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Death receptor 3; Painful bladder syndrome interstitial cystitis; Tumor necrosis factor ligand related molecule 1A

Indexed keywords

APRIL PROTEIN; BETA ACTIN; DEATH RECEPTOR 3; GAPDH PROTEIN; MESSENGER RNA; PROTEIN; TUMOR NECROSIS FACTOR RELATED DEATH LIGAND 1A; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; INTERSTITIAL CYSTITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84869456707     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.778     Document Type: Article

References (29)

1. Clemens JQ, Meenan RT, Rosetti MC, Gao SY and Calhoun EA: Prevalence and incidence of interstitial cystitis in a managed care population. J Urol 173: 98-102, 2005.
2. Choe JH, Son H, Song YS, Kim JC, Lee JZ and Lee KS: Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: A population-based study in Korea. World J Urol 29: 103-108, 2011.
3. Wang ZY and Bjorling DE: Tumour necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells. Inflammation Res 60: 525-532, 2011.
4. Imamura T, Igawa Y, Ogawa T, Homma T, Seki S, Ishizuka O, Satoshi A, Homma Y and Nishizawa O: Expression level of CXCL10 peptide in bladder urothelium and urine as possible biomarkers for diagnosis of ulcerative interstitial cystitis. Eur Urol Suppl 9: 212, 2010.
5. Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T and Hansen AB: YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 57: 371-383, 2010.
6. Ogawa T, Homma T, Igawa Y, Seki S, Ishizuka O, Imamura T, Akahane S, Homma Y and Nishizawa O: CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol 183: 1206-1212, 2010.
7. Lv J, Luo Y, Leng J, Xue W, Liu D and Huang Y: Aberrant expression of monocyte chemoattractant protein-1 (mcp-1) in interstitial cystitis patients. Sci Res Essays 5: 663-667, 2010.
8. Kutlu O, Akkaya E, Koksal IT, Bassorgun IC, Ciftcioglu MA, Sanlioglu S and Kukul E: Importance of TNF-related apop-tosis-inducing ligand in pathogenesis of interstitial cystitis. Int Urol Nephrol 42: 393-399, 2010.
9. Chen MC, Keshavan P, Gregory GD and Klumpp DJ: RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol 292: F1372-F1379, 2007.
10. Zhang N, Sanders AJ, Ye L, Kynaston HG and Jiang WG: Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 30: 87-95, 2010.
11. Song YJ, Meylan F, Botson J, Goldbach-Mansky R, Lee D and Siegel R: TL1A-DR3 interactions are important in both adaptive and innate immunity in inflammatory arthritis. Clin Immunol 135: S88, 2010.
12. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G and Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46, 1997.
13. Gillenwater JY and Wein AJ: Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987. J Urol 140: 203-206, 1988.
14. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
15. Taraban VY, Slebioda TJ, Willoughby JE, Buchan SL, James S, Sheth B, Smyth NR, Thomas GJ, Wang EC and Al-Shamkhani A: Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4: 186-196, 2011.
16. Pobezinskaya YL, Choksi S, Morgan MJ, Cao X and Liu ZG: The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling. J Immunol 186: 5212-5216, 2011.
17. Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, Kwon BS and Lee WH: Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29: 229-235, 2005.
18. Young HA and Tovey MG: TL1A: a mediator of gut inflammation. Proc Natl Acad Sci USA 103: 8303-8304, 2006.
19. Altamirano CV, Pang S, Li LY and Berenson JR: Vascular endo-thelial growth inhibitor (vegi) inhibits the growth of multiple myeloma plasma cells and induces their apoptosis. Blood 98: 638A, 2001.
20. Abdel-Mageed AB and Ghoniem GM: Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J Urol 160: 2000-2003, 1998.
21. Yamada T, Nishimura M and Mita H: Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J Urol 25: 407-413, 2007.
22. Hsieh JH, Chen CY and Kuo HC: Increased apoptosis and decreased junction protein expression of urothelium due to suburothelial inflammation in patients with interstitial cystitis/painful bladder syndrome. Neurourol Urodynamics 29: 1138-1140, 2010.
23. Shie JH, Liu HT and Kuo HC: Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology 79: 484 e7-e13, 2012.
24. Wang W, Zhang N, Zhu XH, He ZS, Wahafu W, Xu ZQ and Yang Y: Involvement of TL1A and DR3 in induction of ischaemia and infammation in urinary bladder dysfunction in the elderly. Mol Med Rep 6: 434-438, 2012.
25. Wang L, Pan W, Zhu FL, Jiao BH, Lou YH, Xiao Y and Qi ZT: Cloning, expression and biological activity of VEGI(151), a novel vascular endothelial cell growth inhibitor. Acta Biochimica Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 32: 485-489, 2000.
26. Chen X, Wu JH, Liu HN, He Z, Gu M, Wang N, Ma J, Hu J, Xia L, He H, Yuan J, Li J, Li L, Li M and Zhu X: Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci 19: 449-457, 2010.
27. Pontari MA, Hanno PM and Ruggieri MR: Comparison of bladder blood flow in patients with and without interstitial cystitis. J Urol 162: 330-334, 1999.
28. Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X and Tuohy VK: Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur Urol 61: 193-200, 2012.
29. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald M P, Forrest JB, Gordon B, Gray M, Mayer RD, Newman D, Nyberg L, Payne CK, Wesselmann U and Faraday MM; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc.: AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185: 2162-2170, 2011.